Testicular Neoplasms
Conditions
Keywords
Cisplatin-based therapy, Ototoxicity, Neurotoxicity
Brief summary
The patients enrolled on this new study will serve as an appropriate comparison group consisting of patients with the diagnosis of germ cell testicular cancer who were cured with surgical resection and did not receive cisplatin-based chemotherapy with a group of patients from another study who did receive cisplatin-based chemotherapy.
Detailed description
Primary Objective To compare the prevalence of ototoxicity and neurotoxicity in GCT cancer survivors who only had surgery to a similar population from The Platinum Study (RSRB45410/1305011509) who received cisplatin-based combination chemotherapy. Secondary Objective To compare the prevalence of obesity, hypertension, and use of antidepressants/anxiolytics in GCT cancer survivors who only had surgery to a similar population from The Platinum Study who received cisplatin-based combination chemotherapy.
Interventions
BEHAVIORALQuestionnaire
* Neurotoxicity * Medications of interest * General health * Family history
Sponsors
Lawrence Einhorn
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis or confirmation of diagnosis of a histologically or serologically confirmed testicular germ cell tumor (GCT) or GCT at another anatomic location * Age at GCT diagnosis: 55 years of age or younger * Males, 18 years of age or older at time of study consent * Subject is able to provide consent * Subject is able to speak and read English * Treatment consisted of surgery only (i.e., orchiectomy and/or retroperitoneal lymph node dissection \[RPLND\]) for either initial testicular germ cell tumor (GCT) or subsequent testicular cancer * Subject completed surgery \> 1 year ago * Subject is currently undergoing active follow-up at IU * Subject did not require any subsequent chemotherapy, salvage chemotherapy treatment or bone marrow transplant. * Subject had no prior chemotherapy of any kind
Exclusion criteria
* Patients with prior chemotherapy (whether for GCT or any other cancer)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients with ototoxicity | 1 year after surgery | The proportion of patients from this study will be compared to the proportion of patients with The Platinum Study. |
| Proportion of patients with neurotoxicity | 1 year after surgery | The proportion of patients from this study will be compared to the proportion of patients with The Platinum Study. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients with obesity | 1 year after surgery | The proportion of patients from this study will be compared to the proportion of patients with The Platinum Study. |
| Proportion of patients with hypertension | 1 year after surgery | The proportion of patients from this study will be compared to the proportion of patients with The Platinum Study. |
| Proportion of patients who use antidepressants/anxiolytics | 1 year after surgery | The proportion of patients from this study will be compared to the proportion of patients with The Platinum Study. |
Countries
United States
Outcome results
None listed